<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729023</url>
  </required_header>
  <id_info>
    <org_study_id>2020KYPJ167</org_study_id>
    <nct_id>NCT04729023</nct_id>
  </id_info>
  <brief_title>Pars Plana Vitrectomy Combined With Phacoemulsification Cataract Surgery in Phakic Diabetes Retinopathy Patients</brief_title>
  <official_title>The Effect of Pars Plana Vitrectomy Combined With Phacoemulsification Cataract Surgery in Phakic Diabetes Retinopathy Patients Over 45 Years Old: a Multicenter Randomized Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Ophthalmic Center, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Ophthalmic Center, Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pars plana vitrectomy (PPV) is one of the most widely used surgical therapies to&#xD;
      proliferative diabetic retinopathy in the world.&#xD;
&#xD;
      However, as a predictable consequence of PPV surgery, postoperative cataract is observed in&#xD;
      79%-95% of phakic diabetes retinopathy patients after PPV in 6-24 months and a subsequent&#xD;
      cataract surgery is usually required. While, the subsequent cataract surgeries not only bring&#xD;
      additional economy and workload burden, but also increase the surgical risks. Since the&#xD;
      two-step surgical approach has its defects, the combination of PPV and phacoemulsification is&#xD;
      an ideal surgical option.&#xD;
&#xD;
      This study is a multi-center prospective study, aimed to evaluate the effect of PPV combined&#xD;
      with phacoemulsification cataract surgery in phakic diabetes retinopathy patients, and make a&#xD;
      comparation between the combined surgery and the two-step surgery in patients without severe&#xD;
      lens opacities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of diabetes retinopathy is increasing dramatically recent years. Pars plana&#xD;
      vitrectomy (PPV) is one of the most widely used surgical therapies to proliferative diabetic&#xD;
      retinopathy in the world.&#xD;
&#xD;
      However, as a predictable consequence of PPV surgery, postoperative cataract is observed in&#xD;
      79%-95% of phakic diabetes retinopathy patients after PPV in 6-24 months.Generally,&#xD;
      subsequent cataract surgeries are required for the phakic patients within 6-16 months after&#xD;
      the PPV surgery to improve visualization. While, the subsequent cataract surgeries not only&#xD;
      bring additional economy and workload burden, but also increase the surgical risks because of&#xD;
      the deep anterior chamber, zonular dehiscence, and inflammation. Since the two-step surgical&#xD;
      approach has its defects, the combination of PPV and phacoemulsification is an ideal surgical&#xD;
      option, which is only suggested in patients with severe lens opacities before the PPV surgery&#xD;
      so far. For those with mild-moderate lens opacities, the benefits of combined surgery is&#xD;
      unknown.&#xD;
&#xD;
      This study is a multi-center prospective study, aimed to evaluate the effect of PPV combined&#xD;
      with phacoemulsification cataract surgery in phakic diabetes retinopathy patients, and make a&#xD;
      comparation between the combined surgery and the two-step surgery in patients without severe&#xD;
      lens opacities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best correct visual acuity (BCVA)</measure>
    <time_frame>Change from Baseline at 1 week after the surgery(s)</time_frame>
    <description>BCVA with early treatment diabetic retinopathy study (ETDRS) letters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best correct visual acuity</measure>
    <time_frame>Change from Baseline at 1 month after the surgery(s)</time_frame>
    <description>BCVA with ETDRS letters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best correct visual acuity</measure>
    <time_frame>Change from Baseline at 3 months after the surgery(s)</time_frame>
    <description>BCVA with ETDRS letters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best correct visual acuity</measure>
    <time_frame>Change from Baseline at 6 months after the surgery(s)</time_frame>
    <description>BCVA with ETDRS letters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VFQ-25 score</measure>
    <time_frame>Change from Baseline at 6 months after the surgery(s).</time_frame>
    <description>Visual Function Questionnaire-25, values from 0-100, the higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Common complications after the surgery like glaucoma, macular edema, iritis, et. al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment costs</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The amount of money paid on the surgery(s) by each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working delay time</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The working delay time due to the surgery(s).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabetic Cataract</condition>
  <arm_group>
    <arm_group_label>Combined surgery group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, all eligible patients will receive pars plana vitrectomy combined with phacoemulsification cataract surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subsequent surgery group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, all eligible patients will receive pars plana vitrectomy first. And a subsequent phacoemulsification will be systematically performed 6 months after the PPV surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pars plana vitrectomy combined with cataract surgery.</intervention_name>
    <description>In the combined surgery group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will receive pars plana vitrectomy combined with phacoemulsification and intraocular lens (IOL) implantation at the same time.</description>
    <arm_group_label>Combined surgery group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pars plana vitrectomy with subsequent cataract surgery.</intervention_name>
    <description>In the control group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will first receive pars plana vitrectomy and a subsequent phacoemulsification with IOL implantation will be performed at least 6 month after the PPV.</description>
    <arm_group_label>Subsequent surgery group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Proliferative diabetes retinopathy ;&#xD;
&#xD;
          2. Age over 45 years old;&#xD;
&#xD;
          3. mild-moderate lens opacities(LOCSⅢ : C3N3P3 or below);&#xD;
&#xD;
          4. recognition of at least one alphabet in ETDRS chart.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Long-standing retinal detachment (more than three months), macular affected&#xD;
&#xD;
          2. Low Vision or blind on the other eye;&#xD;
&#xD;
          3. Macular degeneration, including age-related macular degeneration and Polypoidal&#xD;
             choroidal vasculopathy;&#xD;
&#xD;
          4. Ocular trauma;&#xD;
&#xD;
          5. Glaucoma;&#xD;
&#xD;
          6. Hereditary retinopathy;&#xD;
&#xD;
          7. Severe lens opacities before the surgery (LOCSⅢ : C4N4P4 or above).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mingxing Wu, Ph.D</last_name>
    <phone>+86-13822119558</phone>
    <email>wumingx@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>weibo feng</last_name>
      <email>feng_weibo@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Novak MA, Rice TA, Michels RG, Auer C. The crystalline lens after vitrectomy for diabetic retinopathy. Ophthalmology. 1984 Dec;91(12):1480-4.</citation>
    <PMID>6521988</PMID>
  </reference>
  <reference>
    <citation>Hsuan JD, Brown NA, Bron AJ, Patel CK, Rosen PH. Posterior subcapsular and nuclear cataract after vitrectomy. J Cataract Refract Surg. 2001 Mar;27(3):437-44.</citation>
    <PMID>11255058</PMID>
  </reference>
  <reference>
    <citation>Melberg NS, Thomas MA. Nuclear sclerotic cataract after vitrectomy in patients younger than 50 years of age. Ophthalmology. 1995 Oct;102(10):1466-71.</citation>
    <PMID>9097793</PMID>
  </reference>
  <reference>
    <citation>Blodi BA, Paluska SA. Cataract after vitrectomy in young patients. Ophthalmology. 1997 Jul;104(7):1092-5.</citation>
    <PMID>9224458</PMID>
  </reference>
  <reference>
    <citation>Westesson PL, Lundh H. Temporomandibular joint disk displacement: arthrographic and tomographic follow-up after 6 months' treatment with disk-repositioning onlays. Oral Surg Oral Med Oral Pathol. 1988 Sep;66(3):271-8.</citation>
    <PMID>3174063</PMID>
  </reference>
  <reference>
    <citation>Soto-Hernandez JL, Nunley D, Gutierrez CC, Berk SL. Listeria monocytogenes peritonitis. Am J Gastroenterol. 1988 Feb;83(2):180-2.</citation>
    <PMID>3341344</PMID>
  </reference>
  <reference>
    <citation>Peyman GA, Huamonte F, Goldberg MF. Management of cataract in patients undergoing vitrectomy. Am J Ophthalmol. 1975 Jul;80(1):30-6.</citation>
    <PMID>1155546</PMID>
  </reference>
  <reference>
    <citation>Treumer F, Bunse A, Rudolf M, Roider J. Pars plana vitrectomy, phacoemulsification and intraocular lens implantation. Comparison of clinical complications in a combined versus two-step surgical approach. Graefes Arch Clin Exp Ophthalmol. 2006 Jul;244(7):808-15. Epub 2005 Dec 3.</citation>
    <PMID>16328429</PMID>
  </reference>
  <reference>
    <citation>Biró Z, Kovacs B. Results of cataract surgery in previously vitrectomized eyes. J Cataract Refract Surg. 2002 Jun;28(6):1003-6.</citation>
    <PMID>12036644</PMID>
  </reference>
  <reference>
    <citation>Meyers SM, Klein R, Chandra S, Myers FL. Unplanned extracapsular cataract extraction in postvitrectomy eyes. Am J Ophthalmol. 1978 Nov;86(5):624-6.</citation>
    <PMID>309730</PMID>
  </reference>
  <reference>
    <citation>Smiddy WE, Stark WJ, Michels RG, Maumenee AE, Terry AC, Glaser BM. Cataract extraction after vitrectomy. Ophthalmology. 1987 May;94(5):483-7.</citation>
    <PMID>3601363</PMID>
  </reference>
  <reference>
    <citation>Senn P, Schipper I, Perren B. Combined pars plana vitrectomy, phacoemulsification, and intraocular lens implantation in the capsular bag: a comparison to vitrectomy and subsequent cataract surgery as a two-step procedure. Ophthalmic Surg Lasers. 1995 Sep-Oct;26(5):420-8.</citation>
    <PMID>8963856</PMID>
  </reference>
  <reference>
    <citation>Silva PS, Diala PA, Hamam RN, Arrigg PG, Shah ST, Murtha TL, Schlossman DK, Cavallerano JD, Sun JK, Aiello LP. Visual outcomes from pars plana vitrectomy versus combined pars plana vitrectomy, phacoemulsification, and intraocular lens implantation in patients with diabetes. Retina. 2014 Oct;34(10):1960-8. doi: 10.1097/IAE.0000000000000171.</citation>
    <PMID>24830822</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Retinopathy</keyword>
  <keyword>Diabetic Cataract</keyword>
  <keyword>Pars plana vitrectomy</keyword>
  <keyword>Phacoemulsification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

